First Time Loading...

Altamira Therapeutics Ltd
NASDAQ:CYTO

Watchlist Manager
Altamira Therapeutics Ltd Logo
Altamira Therapeutics Ltd
NASDAQ:CYTO
Watchlist
Price: 1.5 USD
Updated: May 10, 2024
Section:
 

Wall Street
Price Targets

CYTO Price Targets Summary
Altamira Therapeutics Ltd

There are no price targets for CYTO.
CYTO Lowest Forecast
Wall Street Target
Not Available
CYTO Average Forecast
Wall Street Target
Not Available
CYTO Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Altamira Therapeutics Ltd Competitors:
Price Targets
COPN
Cosmo Pharmaceuticals NV
29% Upside
002737
Sunflower Pharmaceutical Group Co Ltd
21% Downside
1477
Ocumension Therapeutics
26% Upside
CORT
Corcept Therapeutics Inc
64% Upside
COPN
Cosmo Pharmaceuticals NV
29% Upside
002737
Sunflower Pharmaceutical Group Co Ltd
21% Downside
1477
Ocumension Therapeutics
26% Upside
CORT
Corcept Therapeutics Inc
64% Upside
603229
Zhejiang Ausun Pharmaceutical Co Ltd
76% Upside
S
4565
Sosei Group Corp
53% Upside
CTLT
Catalent Inc
3% Upside
460
Sihuan Pharmaceutical Holdings Group Ltd
335% Upside

Revenue
Forecast

Revenue Estimate
Altamira Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Altamira Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Altamira Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss
What are analyst estimates?

See Also

Summary
CYTO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYTO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYTO stock valuation using valuation multiples.
Wall Street Estimates
CYTO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYTO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYTO's stock price target?
Not Available

CYTO doesn't have any price targets made by Wall Street professionals.

ALPHA SPREAD
Join more than 136,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.